Viewing Study NCT01137994


Ignite Creation Date: 2025-12-25 @ 1:27 AM
Ignite Modification Date: 2025-12-30 @ 9:32 AM
Study NCT ID: NCT01137994
Status: WITHDRAWN
Last Update Posted: 2013-03-13
First Post: 2010-06-03
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive and p95HER2-positive Metastatic Breast Cancer
Sponsor: GlaxoSmithKline
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module